Targeted, Non-Systemic Therapies for Gastrointestinal Diseases
First Wave BioPharma’s product portfolio is built around its three proprietary technologies – capeserod, a selective 5-HT4 receptor partial agonist which First Wave will pursue for gastrointestinal (GI) indications, the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-inflammatory properties.LEARN MORE
First Wave BioPharma’s GI-disease focused programs span multiple clinical indications ranging from nutritional disorders to diseases brought on by immune malfunction. Disease targets include patient populations with digestive disorders, such as exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis, and inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease.
IN THE NEWS
Feb 13, 2024First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024
Jan 23, 2024First Wave BioPharma to Present at the DealFlow MicroCap Conference
Jan 17, 2024First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico